---

Drugs Used in Ophthalmology - Complete Pharmacology Reference

Table of Contents

1. Ocular Pharmacokinetics - Barriers & Drug Delivery
2. Miotics (Cholinergic Agonists)
3. Mydriatics & Cycloplegics (Muscarinic Antagonists)
4. Sympathomimetics
5. Beta-Adrenergic Blockers (Antiglaucoma)
6. Alpha-2 Agonists (Antiglaucoma)
7. Prostaglandin Analogs
8. Carbonic Anhydrase Inhibitors
9. Rho Kinase (ROCK) Inhibitors
10. Osmotic Agents
11. Topical Anesthetics
12. Anti-infective Agents (Antibacterials, Antivirals, Antifungals, Antiparasitics)
13. Anti-inflammatory Agents (Steroids, NSAIDs)
14. Antiallergic / Antihistamine Agents
15. Anti-VEGF Biologics
16. Immunosuppressants for Dry Eye
17. Surgical Adjuncts
18. Dyes & Diagnostic Agents
19. Ocular Toxicity of Systemic Drugs
20. Preservatives in Ophthalmic Formulations
21. Recent Advances & Novel Drug Delivery

---

1. OCULAR PHARMACOKINETICS - BARRIERS & DRUG DELIVERY

Routes of Administration

Ocular Barriers to Drug Penetration

• Corneal epithelium: Tight junctions limit hydrophilic drug penetration; lipophilic drugs penetrate better
• Blood-aqueous barrier: Tight junctions in ciliary epithelium and iris vessels
• Blood-retinal barrier: Inner (retinal endothelium) and outer (RPE) layers
• Nasolacrimal drainage: Topical drugs drain rapidly, reducing bioavailability and causing systemic absorption via nasal mucosa
• Tear film turnover: ~16% per minute - reduces contact time; only about 5-10 µL of a standard 30-50 µL drop is retained

Pharmacokinetic Factors

• Vehicle/formulation: Gel-forming drops (Timoptic-XE), viscosity enhancers (HPMC), ointments, and sustained-release inserts all increase contact time
• Protein binding: Affects distribution in aqueous humor
• Melanin binding: Drugs like atropine, chloroquine bind to melanin in uveal tissue, creating a depot effect and prolonging action (also source of pigment-related toxicity)

---

2. MIOTICS (PARASYMPATHOMIMETICS - CHOLINERGIC AGONISTS)

Direct-Acting Miotics

Pilocarpine

• Class: Muscarinic receptor agonist (M3)
• Pharmacodynamics:
  • Contracts iris sphincter muscle → miosis (M3 receptor in iris sphincter)
  • Contracts ciliary muscle → accommodation (spasm)
  • In glaucoma: ciliary muscle contraction opens trabecular meshwork by pulling on scleral spur → increases aqueous outflow (conventional/trabecular pathway)
  • Lowers IOP by 20-30%
• Pharmacokinetics:
  • Topical 1-4% solution or 4% gel
  • Onset: 10-30 min; Duration: 4-8 hours (gel: once-daily dosing)
  • Ocusert (pilocarpine-impregnated membrane) provides sustained 7-day release
  • Systemic absorption: minimal at therapeutic doses
• Uses: Open-angle glaucoma (now 4th-line), acute angle-closure glaucoma (emergency), reversal of mydriasis after examination, esotropia (occasionally)
• Side effects: Induced myopia (ciliary spasm), brow ache/headache, decreased night vision (miosis), retinal detachment risk (vitreous traction), systemic - nausea, salivation, diaphoresis (rare)

Carbachol

• Class: Cholinomimetic (muscarinic + nicotinic); resistant to cholinesterase
• Pharmacodynamics: Similar to pilocarpine; also stimulates nicotinic receptors at ganglia
• Uses: Intraocular miosis during cataract/glaucoma surgery (0.01% intraocular); topical glaucoma (rarely now)
• Formulation: 0.01% intraocular solution (preservative-free, Miostat)

Indirect-Acting Miotics (Cholinesterase Inhibitors)

Echothiophate Iodide (Phospholine Iodide)

• Class: Irreversible organophosphate AChE inhibitor
• Pharmacodynamics: Irreversibly phosphorylates active site serine of AChE → massive accumulation of ACh at all muscarinic and nicotinic synapses
• Uses: Accommodative esotropia in children; occasionally refractory glaucoma
• Side effects: Iris cysts (especially in children - prevented by phenylephrine co-administration), cataracts (with prolonged use), systemic cholinergic toxicity if absorbed, contraindicated before succinylcholine (risk of prolonged apnea - AChE inhibition extends duration of succinylcholine)
• ANESTHETIC ALERT: Must be discontinued 4-6 weeks before general anesthesia with succinylcholine

---

3. MYDRIATICS & CYCLOPLEGICS (MUSCARINIC ANTAGONISTS)

Mechanism Summary

• Iris sphincter: M3 receptor blockade → pupil dilation (mydriasis)
• Ciliary muscle: M3 receptor blockade → relaxation → loss of accommodation (cycloplegia)
• Aqueous humor: Slight reduction in production (incidental)

Pharmacokinetics

• Topical absorption through cornea; systemic absorption via nasolacrimal duct
• Duration varies by lipophilicity and receptor binding affinity
• Melanin binding prolongs effect in darkly pigmented eyes

Side Effects

• Ocular: photophobia, blurred near vision, raised IOP in narrow-angle glaucoma (angle closure precipitation - EMERGENCY)
• Systemic (especially atropine in children): tachycardia, flushing, dry mouth, fever, confusion, urinary retention, "hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter"
• Tropicamide lowest systemic risk; Atropine highest due to long duration

Uses

• Diagnostic: Fundus examination, refraction
• Therapeutic: Uveitis (prevent posterior synechiae, relieve ciliary spasm), amblyopia therapy (atropine penalization)
• Surgical: Pre-/intraoperative mydriasis

---

4. SYMPATHOMIMETICS

Phenylephrine (Alpha-1 Agonist)

• Pharmacodynamics: Selective α1 agonist → contracts iris dilator muscle (mydriasis without cycloplegia)
• Uses: Diagnostic mydriasis, combined with cycloplegics to break posterior synechiae in uveitis, decongestant in OTC eye drops
• Concentrations: 2.5% (usual), 10% (reserved for adults; risk of hypertensive crisis)
• Side Effects: Systemic absorption with 10% = hypertensive crisis, reflex bradycardia, arrhythmia; avoid in cardiac disease
• Pharmacokinetics: Rapid onset (15-20 min), duration 3-5 hours

Epinephrine / Dipivefrin

• Dipivefrin: Prodrug of epinephrine (dipivalyl ester); better corneal penetration; converted to epinephrine by corneal esterases
• Mechanism: α + β adrenergic effects → decreases aqueous production (β2) + increases outflow (α1, trabecular and uveoscleral)
• Status: Largely replaced by newer agents due to side effects (cystoid macular edema in aphakic eyes, local reactions)

---

5. BETA-ADRENERGIC BLOCKERS (ANTIGLAUCOMA)

Mechanism

• No effect on aqueous outflow
• Lower IOP by 20-30%

Non-Selective (β1 + β2 Blockers)

Selective (β1 Blocker)

Pharmacokinetics

• Well absorbed through cornea; significant nasolacrimal drainage causes systemic absorption
• Timolol half-life: ~4 hours (plasma); IOP effect 12-24 hrs

Adverse Effects - CRITICAL

• Pulmonary: Bronchospasm (potentially fatal in asthma/COPD) - even β1-selective drugs have risk
• Cardiovascular: Bradycardia, AV block, hypotension, heart failure exacerbation - contraindicated in 2nd/3rd degree AV block, severe bradycardia, overt cardiac failure
• CNS: Depression, fatigue, sexual dysfunction, insomnia
• Metabolic: Masks hypoglycemia symptoms in diabetics; prolongs hypoglycemia; alters lipid profile
• Ocular: Dry eye, punctate keratitis

Contraindications

• Asthma, COPD (all beta-blockers)
• Sinus bradycardia, AV block, cardiac failure
• Depression (relative)
• Infants and neonates (brimonidine preferred)

---

6. ALPHA-2 ADRENERGIC AGONISTS

Brimonidine (0.1%, 0.15%, 0.2%)

• Mechanism: Selective α2 agonist →
  1. Reduces aqueous humor production (via inhibition of cAMP in ciliary epithelium)
  2. Increases uveoscleral outflow
  3. Possible neuroprotective effect (independent of IOP)
• IOP reduction: ~20-25%
• Pharmacokinetics: Crosses blood-brain barrier; peak aqueous humor concentration at 1-2 hrs; systemic half-life ~3 hrs
• Side effects: Ocular allergy (10-20%), conjunctival follicles, drowsiness, dry mouth, headache, fatigue; potentially CNS depression and apnea in neonates/infants - CONTRAINDICATED in children <2 years and premature infants (risk of fatal CNS depression/apnea)
• Advantage over apraclonidine: Less tachyphylaxis, fewer allergic reactions, less systemic alpha-1 effects (no significant pupil dilation)
• Drug interactions: MAO inhibitors (avoid), TCAs (reduce efficacy), CNS depressants (additive)

Apraclonidine (0.5%, 1%)

• Less selective α2, also has α1 activity
• Mainly used short-term perioperatively (prevents IOP spike after laser procedures)
• Higher allergy rate (30-50% long-term) - not suitable for chronic therapy
• Reduces aqueous production primarily

---

7. PROSTAGLANDIN ANALOGS (PROSTAMIDES)

Mechanism

• Act at FP receptors (prostaglandin F receptors) on ciliary muscle
• Increase uveoscleral outflow (unconventional pathway) - relax ciliary muscle extracellular matrix, upregulate matrix metalloproteinases (MMPs) → remodel tissue → increased flow through ciliary body face and suprachoroidal space
• Some also increase trabecular outflow slightly
• IOP reduction: 25-35% (most powerful class)
• Once-daily evening dosing (maximum effect during night/morning when IOP tends to peak)

Agents

Pharmacokinetics

• Prodrugs (except bimatoprost which is a prostamide): hydrolyzed by corneal esterases to active free acid
• Onset: 3-4 hours; peak at 8-12 hours; duration 24 hours
• Minimal systemic exposure from once-daily topical use
• Active acid enters systemic circulation, metabolized hepatically

Side Effects (Unique to Class)

• Iris heterochromia: Irreversible increase in brown iris pigmentation (increased melanin synthesis in iris melanocytes) - particularly in green-hazel or blue/grey-brown irides; occurs in ~10% over years
• Periorbital changes (prostaglandin-associated periorbitopathy - PAP): Upper eyelid deepening/sulcus, lower lid fat atrophy, enophthalmos, ptosis - caused by periorbital fat atrophy
• Eyelash changes: Increased length, thickness, number, and pigmentation (trichomegaly)
• Conjunctival hyperemia (bimatoprost > others)
• Reactivation of herpes simplex keratitis
• Macular edema in aphakic/pseudophakic patients - use with caution
• Systemic: flu-like symptoms (rare), joint/back pain

---

8. CARBONIC ANHYDRASE INHIBITORS (CAIs)

Mechanism

• Carbonic anhydrase (CA) in non-pigmented ciliary epithelium catalyzes: HCO₃⁻ + H⁺ ↔ H₂O + CO₂ (via CA-II and CA-XII isoforms)
• Inhibition of CA reduces bicarbonate secretion → reduces Na+/H₂O transport into posterior chamber → reduces aqueous production by 30-50%
• Does NOT affect outflow

Topical CAIs

• Pharmacokinetics: Penetrate corneal epithelium; distribute to red blood cells (bind to CA in RBCs) → long half-life in blood; renal excretion
• Side effects: Ocular stinging/burning (dorzolamide > brinzolamide), bitter taste, superficial punctate keratitis, allergic reactions; systemic effects rare but possible (sulfonamide allergy - cross-reactivity)
• Contraindication: Sulfonamide allergy; severe renal impairment

Oral/Systemic CAIs

• Side effects (oral): Paresthesias (hands/feet), malaise, fatigue, anorexia, depression, nephrolithiasis (calcium oxalate stones), metabolic acidosis, aplastic anemia (rare but serious), hypokalemia; Stevens-Johnson syndrome (rare)
• Contraindications: Sulfonamide hypersensitivity, adrenal insufficiency, hyponatremia/hypokalemia, hepatic cirrhosis, sickle cell disease

---

9. RHO KINASE (ROCK) INHIBITORS

Netarsudil (Rhopressa, 0.02%)

• Newest class of antiglaucoma drugs (FDA approved 2017)
• Mechanism (triple action):
  1. Rho kinase inhibition: Relaxes trabecular meshwork contractile cells → increases conventional (trabecular) outflow
  2. Norepinephrine transporter (NET) inhibition: Reduces sympathetic tone in ciliary body → reduces aqueous production
  3. Reduces episcleral venous pressure: Contributes to IOP lowering
• IOP reduction: ~20-25%; once-daily dosing
• Unique advantage: Works on trabecular meshwork (unlike prostaglandins which act on uveoscleral route) - can be additive with PGAs
• Pharmacokinetics: Undergoes intracorneal esterase hydrolysis to active metabolite AR-13503; rapid onset
• Side effects: Conjunctival hyperemia (most common, ~50%), subconjunctival hemorrhage, corneal verticillata (gold-brown corneal deposits - dose-dependent, reversible), blepharitis, increased tearing, pain

Roclatan (Netarsudil 0.02% + Latanoprost 0.005%)

• Fixed-dose combination; once daily
• Additive ~8-9 mmHg IOP reduction (MERCURY 1 & 2 trials)

---

10. OSMOTIC AGENTS

Mechanism

• Create osmotic gradient between plasma and vitreous/aqueous → draw water out of the eye → rapidly reduce IOP
• Used for acute IOP elevation, preoperative vitreous dehydration

• Side effects: Headache (volume shift), nausea/vomiting, electrolyte disturbances, pulmonary edema (heart failure), urinary retention (urologist alert); acute tubular necrosis with mannitol in renal failure

---

11. TOPICAL OCULAR ANESTHETICS

Mechanism

• Block voltage-gated Na+ channels → stabilize neuronal membrane → prevent action potential propagation in sensory corneal/conjunctival nerves
• No effect on pupil or IOP

Important Notes

• Topical anesthetics are NOT to be dispensed for home use: Repeated use causes corneal epithelial toxicity, delayed healing, stromal infiltrates, corneal ulceration - suppress pain so patients ignore injury
• Used only in office/surgical setting
• Local infiltration/nerve blocks: Bupivacaine (long-acting), lidocaine used for retrobulbar/peribulbar anesthesia for intraocular surgery

---

12. ANTI-INFECTIVE OPHTHALMIC AGENTS

12a. Antibacterials

Fluoroquinolones (Preferred for bacterial keratitis and endophthalmitis prophylaxis)

• Mechanism: Inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV → prevent DNA replication, transcription, repair
• Spectrum: Broad gram-positive and gram-negative; some anaerobic activity (moxifloxacin)

Aminoglycosides

• Mechanism: Bind 30S ribosomal subunit → inhibit protein synthesis; bactericidal
• Tobramycin 0.3%: Excellent gram-negative coverage (Pseudomonas); combined with dexamethasone (Tobradex)
• Gentamicin 0.3%: Similar spectrum; more corneal toxicity
• Neomycin: Combined preparations; high allergy rate (10-15%)

Macrolides

• Azithromycin 1% (AzaSite): Inhibits 50S subunit; good for Chlamydia trachomatis (trachoma), blepharitis, bacterial conjunctivitis; advantages: once-daily dosing, prolonged retention in ocular tissues

Chloramphenicol

• Broad spectrum; bacteriostatic (binds 50S, inhibits peptidyl transferase)
• Risk of aplastic anemia (rare, dose-independent, idiosyncratic) - limits systemic use; topical ophthalmic use considered acceptable
• Available as eye drops and ointment; widely used in UK

Tetracyclines

• Tetracycline ointment: Trachoma (WHO recommended), Chlamydia, rosacea blepharitis
• Doxycycline (oral): Meibomian gland dysfunction, ocular rosacea - modulates MMP activity, reduces inflammatory cytokines

Polymyxin B Combinations

• Polymyxin B + trimethoprim (Polytrim): Broad coverage; first-line for bacterial conjunctivitis (children)
• Polymyxin B + neomycin + gramicidin/bacitracin (Neosporin): Classic broad-spectrum; common sensitizer

12b. Antiviral Agents

Herpetic Eye Disease

• Dendritic corneal ulcer (HSV): Topical acyclovir ointment 5x/day or ganciclovir 0.15% gel 5x/day; debridement
• HSV stromal keratitis: Add topical steroids (with antiviral cover) to reduce immune-mediated stromal damage
• Herpes Zoster Ophthalmicus: Oral acyclovir/valacyclovir/famciclovir within 72h; prevents ocular complications

12c. Antifungal Agents

• Source: Goodman & Gilman's, Table 74-6

12d. Antiparasitic Agents

• Acanthamoeba keratitis: Topical propamidine isethionate (Brolene) + polyhexamethylene biguanide (PHMB) or chlorhexidine (both compounded); adjunct: oral miltefosine (FDA-approved for leishmaniasis; off-label)
• Toxoplasmosis chorioretinitis: Pyrimethamine + sulfadiazine + folinic acid (leucovorin) ± clindamycin ± oral steroids; alternative: TMP-SMX ± clindamycin
• Onchocerciasis (river blindness): Ivermectin (oral) - kills microfilariae

---

13. ANTI-INFLAMMATORY AGENTS

13a. Corticosteroids

Mechanism

• Bind intracellular glucocorticoid receptors (GRs) → GR-drug complex translocates to nucleus → binds glucocorticoid response elements (GREs) → upregulates anti-inflammatory proteins (lipocortin/annexin-1, IL-10)
• Inhibits phospholipase A2 (via annexin-1) → reduces arachidonic acid release → reduces prostaglandins + leukotrienes
• Reduces vascular permeability, inhibits leukocyte migration, suppresses cytokine production
• Stabilizes lysosomal membranes

Potency Classification (Ophthalmic)

• Prednisolone acetate 1% (Pred Forte): Gold standard; suspension; must be shaken well
• Dexamethasone 0.1%: High potency; phosphate form better penetration
• Difluprednate 0.05% (Durezol): Difluorinated; potent; less frequent dosing; higher IOP risk

• Fluorometholone 0.1%, 0.25% (FML): Less IOP elevation and cataract risk; less penetration; good for conjunctival disease
• Medrysone 1%: Lowest penetration; limited to conjunctival/allergic use

• Loteprednol etabonate 0.2%, 0.5% (Lotemax, Alrex): "Retrometabolic" design; undergoes predictable inactivation after receptor binding; significantly less IOP elevation and cataract risk; now available as 0.5% gel and 1% suspension

• Rimexolone 1% (Vexol): For post-op inflammation, anterior uveitis

Uses

• Anterior uveitis/iritis, allergic conjunctivitis (severe), post-surgical inflammation, corneal graft rejection, vernal keratoconjunctivitis, episcleritis, scleritis, inflammatory conditions of posterior segment (periocular/intravitreal)

Routes in Posterior Segment

• Sub-Tenon's triamcinolone 40 mg: Posterior uveitis, CMO
• Intravitreal triamcinolone 4 mg: DME, BRVO-associated CMO; reactivates latent ocular infections
• Ozurdex (dexamethasone intravitreal implant 0.7 mg): Biodegradable PLGA implant; ~6 months duration; approved for DME, BRVO/CRVO, non-infectious posterior uveitis
• Iluvien (fluocinolone acetonide implant 0.19 mg): Non-biodegradable; ~36 months duration; approved for chronic DME

Adverse Effects - Ocular (Dose and Duration Dependent)

1. Raised IOP (steroid glaucoma): Mechanism - steroids increase trabecular meshwork glycosaminoglycans → reduced outflow; affects ~30% of general population ("steroid responders"); can lead to irreversible glaucoma
2. Posterior subcapsular cataracts (PSC): With prolonged topical or systemic use; mechanism relates to inhibition of lens epithelial cell differentiation
3. Infection activation/worsening: Herpes simplex, fungal, bacterial; never use steroids alone on "red eye" without diagnosis
4. Impaired wound healing
5. Increased risk of perforation in corneal ulcers

13b. NSAIDs (Ophthalmic)

Mechanism

• Inhibit cyclooxygenase (COX-1 and COX-2) → reduce prostaglandin synthesis in ocular tissues → reduce inflammation and pain without IOP elevation

Adverse Effects

• Corneal toxicity/melting (prolonged use post-keratorefractive surgery - especially diclofenac)
• Superficial punctate keratitis, burning/stinging
• Delay epithelial healing
• Precipitation of angle closure (via prostaglandin inhibition)

---

14. ANTIALLERGIC / ANTIHISTAMINE AGENTS

H1 Antihistamines with Mast Cell Stabilizers (Dual Action - Preferred)

Pure Mast Cell Stabilizers

Pure H1 Antihistamines (Topical, Older)

• Levocabastine 0.05% (highly selective H1; minimal mast cell effect)
• Emedastine 0.05%

Pharmacodynamics of Mast Cell Stabilizers

• Inhibit IgE-mediated calcium influx into mast cells → prevent degranulation → reduce release of histamine, prostaglandins, leukotrienes, cytokines
• Must be started BEFORE allergen exposure; not effective for immediate relief

---

15. ANTI-VEGF BIOLOGICS (INTRAVITREAL)

Vascular Endothelial Growth Factor (VEGF) Pathway

• VEGF-A (multiple isoforms: VEGF-A121, 165, 189, 206) is the primary driver
• VEGF-A binds VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1)
• VEGFR-2 signaling mediates: angiogenesis, vascular permeability, endothelial proliferation, migration
• In eye: VEGF-A overexpression drives choroidal neovascularization (CNV in AMD), retinal neovascularization (PDR), macular edema (BRVO/CRVO/DME)
• VEGF-B, VEGF-C, VEGF-D, PlGF also relevant (PlGF important in AMD)

Agents

Pegaptanib (Macugen)

• Type: RNA aptamer (binds and neutralizes VEGF-A165 isoform only)
• Dose: 0.3 mg intravitreal every 6 weeks
• Status: First FDA-approved anti-VEGF for wet AMD (2004); largely replaced by ranibizumab/bevacizumab

Ranibizumab (Lucentis)

• Type: Humanized monoclonal antibody Fab fragment (no Fc region)
• Target: All VEGF-A isoforms
• Dose: 0.5 mg/0.05 mL intravitreal monthly (or PRN/treat-and-extend)
• Half-life: ~9 days in vitreous; Fc-free design reduces systemic absorption
• FDA indications: Wet AMD, DME, BRVO/CRVO-associated macular edema, diabetic retinopathy, myopic CNV
• Clinical trials: MARINA, ANCHOR, RIDE/RISE, BRAVO/CRUISE, RESTORE

Bevacizumab (Avastin)

• Type: Full-length humanized IgG1 monoclonal antibody (Fc intact)
• Original indication: Colorectal cancer (IV)
• Ophthalmic use: Off-label (but widely used globally - cost-effective)
• Target: All VEGF-A isoforms
• Dose: 1.25 mg/0.05 mL intravitreal
• Half-life: Longer than ranibizumab (intact Fc → FcRn recycling)
• CATT Trial: Non-inferior to ranibizumab for visual acuity in wet AMD; significantly cheaper
• Compounding issue: Must be aseptically compounded from IV vials; contamination risk; shelf-life considerations

Aflibercept (Eylea, VEGF Trap)

• Type: Recombinant fusion protein - VEGFR-1 domain 2 + VEGFR-2 domain 3 fused to Fc of IgG1
• Targets: VEGF-A (all isoforms), VEGF-B, PlGF-1 and PlGF-2 (broader than ranibizumab/bevacizumab)
• Dose: 2 mg/0.05 mL; standard monthly × 3 then every 8 weeks; now high-dose 8 mg (Eylea HD/Eylea 8 mg) - q12-16 week dosing possible (PULSAR, PHOTON trials)
• Half-life in vitreous: ~9 days; VEGF-binding affinity significantly higher than ranibizumab
• FDA indications: Wet AMD, DME, BRVO/CRVO, diabetic retinopathy, ROP (retinopathy of prematurity - 2023 approval for ROP)

Faricimab (Vabysmo) - NEWEST FDA APPROVED (2022)

• Type: First bispecific antibody in ophthalmology; full IgG1 format
• Dual targets:
  1. VEGF-A (via ranibizumab-derived arm)
  2. Angiopoietin-2 (Ang-2) (via novel arm) - Ang-2 inhibition stabilizes vasculature, reduces inflammation and leakage (Tie-2 signaling pathway)
• Mechanism advantage: Ang-2 is upregulated in retinal disease and promotes VEGF-mediated destabilization; blocking both pathways simultaneously = synergistic stabilization
• Dose: 6 mg intravitreal; loading phase then q8-16 week personalized interval possible
• Clinical Trials:
  • TENAYA/LUCERNE (wet AMD): Non-inferior to aflibercept; 45-46% achieved q16-week dosing
  • YOSEMITE/RHINE (DME): Superior or non-inferior to aflibercept at 2 years; ~51-53% on q16-week dosing
  • BALATON/COMINO (RVO): 2024 Phase 3 data - superior to ranibizumab at 24 weeks (PMID 38280653); 72-week treat-and-extend results published 2025 (PMID 40107501)
  • MAGIC trial (Phase 2, non-proliferative DR): Ongoing (PMID 41587134)
• Source: TENAYA/LUCERNE anatomic outcomes, 2025

Brolucizumab (Beovu)

• Type: Single-chain antibody fragment (scFv) - smallest anti-VEGF biologic
• Target: All VEGF-A isoforms
• Advantage: Small size → higher molar concentration per injection; potentially longer durability (q12-week dosing)
• Serious adverse effect: Retinal vasculitis and retinal artery occlusion (rare ~3-4%; some cases severe vision loss) - requires careful monitoring; patients with prior ocular inflammation may be at higher risk

Conbercept (KH902) - Used in China

• Fusion protein similar to aflibercept; targets VEGF-A, VEGF-B, PlGF, VEGF-C

Recent Advances: Port Delivery System (PDS)

• Susvimo (ranibizumab PDS implant): Refillable intraocular implant surgically implanted in pars plana; delivers ranibizumab continuously; refilled every ~6 months; reduces injection burden; FDA approved 2021 (wet AMD), 2023 (DME); long-term trials (Archway) show non-inferiority to monthly injections

---

16. IMMUNOSUPPRESSANTS FOR DRY EYE

Cyclosporine A (Restasis 0.05%, Cequa 0.09%)

• Mechanism: Inhibits calcineurin → prevents dephosphorylation of NFAT → reduces T-cell activation and inflammatory cytokine (IL-2, IFN-γ, TNF) production in lacrimal gland → reduces T-lymphocyte mediated inflammation in ocular surface
• Increases goblet cell density, increases tear production by reducing lacrimal gland inflammation
• Pharmacokinetics: Topical; very low systemic absorption; nanoemulsion vehicle (Cequa 0.09% uses nanomicellar technology for better delivery); onset of clinical effect: 3-6 months
• Side effects: Burning/stinging (most common), redness
• Formulations: Restasis = 0.05% cationic nanoemulsion; Cequa = 0.09% nanomicellar

Lifitegrast (Xiidra 5%)

• Mechanism: LFA-1 (lymphocyte function-associated antigen-1, an integrin on T-cells) antagonist → blocks LFA-1 from binding ICAM-1 (intercellular adhesion molecule-1 on antigen-presenting cells) → inhibits T-cell activation and migration to ocular surface → reduces inflammation
• Novel mechanism: blocks the first step in T-cell activation at the ocular surface
• Pharmacokinetics: Topical BD; minimal systemic absorption
• Onset: Faster than cyclosporine (some benefit within 2 weeks for symptoms)
• Side effects: Instillation site discomfort, dysgeusia (altered taste - drug drains via nasolacrimal duct), transient visual disturbance

Topical Corticosteroids (Pulse therapy) for Dry Eye

• Short-term loteprednol, fluorometholone for acute flares; reduces inflammatory initiation cycle

---

17. SURGICAL ADJUNCTS IN OPHTHALMOLOGY

Antifibrotic Agents (Glaucoma Surgery Adjuncts)

• 5-Fluorouracil (5-FU): Pyrimidine analog; inhibits thymidylate synthase → inhibits DNA synthesis in fibroblasts → reduces subconjunctival scarring after trabeculectomy; given subconjunctivally intraoperatively or postoperatively (5 mg injections)
• Mitomycin C (MMC): Alkylating agent (crosslinks DNA); much more potent antifibrotic; single intraoperative application at trabeculectomy site (0.2-0.4 mg/mL for 1-5 minutes); also used in pterygium surgery (anti-recurrence), PRK (prevents haze), conjunctival/corneal tumors
• Risks: Thin avascular blebs → bleb leak, endophthalmitis; hypotony; limbal stem cell deficiency; corneal/scleral melt

Viscoelastics (Ophthalmic Viscosurgical Devices - OVDs)

• Sodium hyaluronate (Healon, Provisc): Highly viscous; maintains anterior chamber space, protects endothelium
• Hydroxypropylmethylcellulose (HPMC): Less viscous; less protection but easier removal
• Dispersive OVDs (Viscoat): Protect corneal endothelium better; used in phacoemulsification
• Cohesive OVDs (Healon GV): Better space maintenance; easier to remove

Intraocular Gases and Silicone Oil (Vitreoretinal Surgery)

• SF6 (20%): Lasts ~2 weeks; tamponade for retinal detachment
• C3F8 (14%): Lasts ~6-8 weeks; macular hole surgery
• Air: Shortest duration; pneumatic retinopexy
• Silicone oil: Permanent (must be removed surgically); complex retinal detachments; high risk proliferative vitreoretinopathy

Tissue Plasminogen Activator (tPA)

• Mechanism: Serine protease; converts plasminogen to plasmin → lyses fibrin clots
• Intravitreal use: Sub-retinal hemorrhage (submacular), intravitreal hemorrhage
• Intracameral use: Fibrin in anterior chamber post-surgery

Botulinum Toxin Type A (Botox)

• Mechanism: Cleaves SNAP-25 (synaptosomal-associated protein) → prevents ACh vesicle fusion → blocks neuromuscular transmission at extraocular muscles → temporary paralysis
• Ophthalmic uses: Strabismus treatment (weaken overacting muscle), blepharospasm, hemifacial spasm, entropion, cosmetic (periorbital wrinkles), thyroid eye disease (lid retraction)
• Duration: 3-4 months; repeat injections needed

---

18. DYES AND DIAGNOSTIC AGENTS

Fluorescein Sodium

• Type: Xanthene dye
• IV fluorescein angiography (FFA): 10-25% IV injection → rapid distribution to choroidal and retinal vessels → identifies CNV, ischemia, leakage; side effects include nausea/vomiting, skin yellowing (transient), anaphylaxis (rare, 1:2000)
• Topical: 0.25-2% strips or drops; stains denuded corneal epithelium (green with blue light); used for contact lens fitting, Goldman applanation tonometry (with 0.25% fluorescein + topical anesthetic)

Indocyanine Green (ICG)

• IV: Used for ICG angiography - penetrates through melanin/pigment → better visualization of choroidal circulation, polypoidal choroidal vasculopathy (PCV); binds plasma proteins
• Intravitreal: Vital dye for ILM (internal limiting membrane) staining during macular surgery (macular hole, ERM peeling)
• Side effects: Nausea, urticaria; contraindicated in iodine/shellfish allergy (contains iodine)

Brilliant Blue G (BBG) / Trypan Blue

• Intravitreal BBG: Stains ILM selectively (replacing ICG); safer profile
• Intracameral Trypan Blue 0.06%: Stains anterior capsule of lens for capsulorhexis in cataract surgery (especially white cataracts)

---

19. OCULAR TOXICITY OF SYSTEMIC DRUGS

---

20. PRESERVATIVES IN OPHTHALMIC FORMULATIONS

Preservative-Free (PF) Formulations

• Unit-dose vials (UDVs/minims): Single-use; no preservative needed; recommended for:
  • Patients using >3 drops daily (high drop burden)
  • Contact lens wearers
  • Dry eye patients
  • Pre/post-operative period
• Examples: Tafluprost PF (Saflutan), Preservative-free timolol, many lubricants
• A 2025 systematic review (PMID 41465776) confirmed that switching from preserved to PF prostaglandins significantly improves ocular surface parameters including corneal staining and TBUT

---

21. RECENT ADVANCES AND NOVEL DRUG DELIVERY

Gene Therapy

• Voretigene neparvovec (Luxturna): AAV2 vector delivering functional RPE65 gene; for RPE65-mutant Leber's congenital amaurosis / retinitis pigmentosa; subretinal injection; FDA approved 2017
• GT005 (Gyroscope): AAV-mediated complement factor I delivery for geographic atrophy - ongoing trials
• ADVM-022: Intravitreal AAV gene therapy delivering aflibercept gene construct; Phase 1/2 OPTIC trial ongoing
• 4D-150: Dual-target intravitreal gene therapy (VEGF-C + VEGF-A); Phase 2 PRISM trial for wet AMD

Port Delivery System

• Susvimo (ranibizumab implant): Surgical device implanted in pars plana; continuous drug release; refilled every 6 months; reduces injection burden

Sustained-Release Implants

• Ozurdex (dexamethasone 0.7 mg biodegradable PLGA implant): Approved; ~6 months
• Iluvien (fluocinolone acetonide 0.19 mg non-biodegradable): Approved; ~3 years
• Durysta (bimatoprost SR 10 µg biodegradable implant, intracameral): FDA approved 2020 for OAG; single biodegradable pellet placed in anterior chamber angle; releases bimatoprost for ~4 months; reduces injection frequency

Nanoparticle Drug Delivery

• Polymeric nanoparticles (PLGA, chitosan): Controlled release across ocular barriers; improved bioavailability
• Lipid nanoparticles (LNPs): Delivery of RNA therapeutics (siRNA, mRNA) to retina; active research area
• Mesoporous silica nanoparticles: Customizable surface chemistry; prolonged release (2026 review, PMID 42086969)
• Cyclodextrins: Complexing agents to solubilize lipophilic drugs in aqueous vehicles
• Contact lens drug delivery: Drug-impregnated contact lenses for sustained topical delivery

Micro/Nano Devices

• Microneedles: Minimally invasive delivery to suprachoroidal space or sclera; bypass subconjunctival barriers
• Suprachoroidal delivery: CLS-TA (triamcinolone acetonide suprachoroidal) - FDA approved 2021 (Xipere) for macular edema from uveitis

RNA Therapeutics

• Sirolimus (rapamycin): mTOR inhibitor; intravitreal for non-infectious uveitis (studies)
• Antisense oligonucleotides/siRNA: Experimental for AMD, DR, glaucoma neuroprotection
• Gene editing (CRISPR): Preclinical for dominant forms of RP

Emerging Antiglaucoma Targets

• Adenosine receptor agonists: A1 receptors in trabecular meshwork increase outflow
• Serotonin receptor modulators: 5-HT2A agonism increases uveoscleral outflow
• Neuroprotective agents: NMDA antagonists (memantine - failed Phase 3); CNTF (ciliary neurotrophic factor) - NT-501 implant (Renexus) for glaucoma neuroprotection under investigation
• Brimonidine neuroprotection: Independent of IOP lowering; activates Bcl-2 pathways, reduces RGC apoptosis

Dry Eye Advances

• Perfluorohexyloctane (PFHO) (Miebo 100%): FDA approved 2023 for dry eye associated with meibomian gland dysfunction; first drug specifically targeting evaporative dry eye; mechanism - semifluorinated alkane that reduces aqueous evaporation by stabilizing lipid layer; once-daily
• Varenicline nasal spray (Tyrvaya 0.03 mg): FDA approved 2021 for dry eye; intranasal delivery stimulates trigeminal-lacrimal reflex → increases basal tear production; mechanism: partial nicotinic acetylcholine receptor agonist on nasal mucosa
• REGN-A1H: Anti-Ang-2 + anti-VEGF for dry eye - experimental

---

SUMMARY: ANTIGLAUCOMA DRUG COMBINATIONS

---

• Goodman & Gilman's The Pharmacological Basis of Therapeutics, Chapter 74 (Ophthalmology) - direct textbook reading
• Katzung's Basic and Clinical Pharmacology, 16th Ed
• Faricimab TENAYA/LUCERNE Phase 3: PMID 39617060
• Faricimab BALATON/COMINO RVO: PMID 38280653
• Faricimab YOSEMITE/RHINE epiretinal outcomes: PMID 40668667
• Preservative-free prostaglandins review: PMID 41465776
• Mesoporous nanoparticles for ocular delivery: PMID 42086969
• Dry eye advances & drug delivery systems: PMID 41994442

---

Complete Mechanisms of Action - Ophthalmic Drugs

FOUNDATIONAL PHYSIOLOGY: Aqueous Humor Dynamics

• Two-thirds formed by the ciliary body (non-pigmented ciliary epithelium) via active secretion - Na⁺/K⁺-ATPase actively pumps Na⁺ into the posterior chamber; bicarbonate (HCO₃⁻) and Cl⁻ follow passively; water follows osmotically. Carbonic anhydrase (CA-II and CA-XII isoforms) catalyzes CO₂ + H₂O → H₂CO₃ → H⁺ + HCO₃⁻, providing the bicarbonate for this transport.
• One-third by passive ultrafiltration from iris vessels

1. Trabecular (conventional) pathway (~80-90%): Aqueous flows from posterior chamber → pupil → anterior chamber → trabecular meshwork (TM) → Schlemm's canal → collector channels → episcleral veins → systemic circulation. This is a pressure-dependent, flow-resistance pathway. The juxtacanalicular tissue (innermost TM layer, just adjacent to Schlemm's canal) provides the majority of outflow resistance.
2. Uveoscleral (unconventional) pathway (~10-20%): Aqueous passes through the root of the iris and ciliary muscle spaces → supraciliary and suprachoroidal spaces → exits via scleral emissaria. This route is largely pressure-independent.

---

I. CHOLINERGIC (MUSCARINIC) AGONIST MECHANISMS

Pilocarpine - Step-by-Step Mechanism

• IP₃ (inositol 1,4,5-trisphosphate) → opens IP₃-gated Ca²⁺ channels on sarcoplasmic reticulum → [Ca²⁺]ᵢ rises
• DAG (diacylglycerol) → activates PKC (protein kinase C) → phosphorylates myosin light chain kinase (MLCK)

• Iris sphincter muscle (circumferential ring) contracts → pupil constricts
• In angle-closure glaucoma: miosis mechanically pulls iris away from trabecular meshwork → opens the drainage angle → reduces resistance → lowers IOP acutely

• Ciliary muscle is a ring-shaped muscle; contraction causes it to move anteriorly and inward
• This relaxes the zonular fibers → lens becomes more spherical → accommodation (near focus)
• More importantly for glaucoma: contraction pulls the scleral spur posteriorly and outward → mechanically opens the trabecular meshwork (widening inter-trabecular spaces) → increases conventional outflow → lowers IOP
• This is the primary mechanism in open-angle glaucoma

Pilocarpine
    ↓ binds M3 (Gq)
    ↓ PLC-β → IP3 + DAG
    ↓ IP3 → Ca²⁺ release
    ↓ Ca²⁺-CaM → MLCK activated
    ↓ Myosin phosphorylated
    ↓ Smooth muscle contraction
    ↙               ↘
Iris sphincter    Ciliary muscle
contracts         contracts
    ↓               ↓
 Miosis         Pulls scleral spur
(angle opens    → TM opens
in ACG)         → ↑ trabecular outflow
                → ↓ IOP (OAG)

Echothiophate - Indirect Mechanism (Anticholinesterase)

1. Echothiophate phosphorylates the serine-OH in the esteratic active site (covalent bond)
2. Forms an extremely stable phosphorylated AChE → irreversible inhibition (unlike carbamates, which are reversible)
3. ACh accumulates at all cholinergic synapses → continuous muscarinic stimulation → sustained miosis + ciliary contraction → ↑ trabecular outflow → ↓ IOP
4. Aging: With time (24-48 hrs), the phosphorylated enzyme undergoes "aging" (dealkylation) → becomes permanently refractory to reactivation by pralidoxime
5. Recovery only occurs via synthesis of new AChE enzyme (weeks)

• Echothiophate also inhibits plasma cholinesterase (pseudocholinesterase)
• Succinylcholine is normally hydrolyzed by plasma cholinesterase in 3-5 minutes
• With echothiophate: succinylcholine half-life extends to 20-30 minutes → prolonged neuromuscular blockade → apnea → must discontinue 4-6 weeks before surgery using succinylcholine

---

II. MUSCARINIC ANTAGONIST MECHANISMS (MYDRIATICS/CYCLOPLEGICS)

• These drugs competitively bind M3 receptors on iris sphincter and ciliary muscle WITHOUT activating Gq signaling
• Block the binding of acetylcholine → prevent Gq → PLC-β → IP3 → Ca²⁺ pathway → NO contraction
• Result: Sympathetic tone is unopposed

• Iris sphincter paralyzed → iris dilator (alpha-1 adrenergic, sympathetically innervated) is unopposed → mydriasis

• Ciliary muscle relaxed → zonular fibers under tension → lens flattened → cycloplegia (paralysis of accommodation)
• TM tension reduced: With ciliary muscle relaxed, scleral spur is no longer pulled → TM inter-trabecular spaces may narrow slightly → slight outflow reduction (explains why these can precipitate angle closure)

• Atropine: very high affinity for M3, slow dissociation rate → 7-14 days
• Tropicamide: low affinity, rapid dissociation → 4-6 hours
• Cyclopentolate: intermediate affinity + significant blood-ocular barrier penetration → excellent cycloplegia for 12-24 hrs

1. Mydriasis → lens-iris contact increases → aqueous cannot flow through pupil → pupillary block → aqueous pressure builds in posterior chamber → iris bulges forward (iris bombe) → peripheral iris occludes TM → acute angle closure glaucoma (medical emergency)
2. Most dangerous in patients with shallow anterior chamber, thick peripheral iris, hypermetropes

---

III. BETA-ADRENERGIC BLOCKER MECHANISMS

Normal β-adrenergic signaling in ciliary body:

Norepinephrine/Epinephrine → β₂ receptor (Gs-coupled)
    ↓ Gαs activates adenylyl cyclase (AC)
    ↓ AC converts ATP → cAMP (↑ intracellular cAMP)
    ↓ cAMP activates PKA (protein kinase A)
    ↓ PKA phosphorylates ion channels and transport proteins
    ↓ Increases Na⁺/K⁺-ATPase activity + Cl⁻ secretion
    ↓ Water follows osmotically into posterior chamber
    → Aqueous humor PRODUCED

Beta-blocker mechanism:

Timolol (β₁ + β₂ blocker) → competitive antagonism at β₂ receptor on NPE
    ↓ Blocks Gαs activation → ↓ adenylyl cyclase
    ↓ ↓ cAMP → ↓ PKA activity
    ↓ ↓ Na⁺/K⁺-ATPase activity + ↓ Cl⁻ transport
    ↓ Less water secreted into posterior chamber
    → ↓ Aqueous humor PRODUCTION (~30-50%)
    → ↓ IOP (~20-30%)

• Ciliary body β-receptors are predominantly β₂ subtype
• Betaxolol's β₁ selectivity means it does not fully block the β₂ receptors driving aqueous production
• Net result: ~10-15% less IOP lowering than timolol
• But betaxolol has another effect: it blocks voltage-gated L-type Ca²⁺ channels in retinal ganglion cells → potential neuroprotective effect independent of IOP (may maintain retinal blood flow)

• Nasolacrimal drainage → systemic absorption → same β-blockade effects as oral beta-blockers
• β₁ blockade in heart → bradycardia, AV nodal depression, negative inotropy
• β₂ blockade in lungs → bronchospasm (particularly dangerous in asthma/COPD)
• β₂ blockade in pancreas → impairs glucagon-mediated glycogenolysis → hypoglycemia unawareness in diabetics

---

IV. ALPHA-2 ADRENERGIC AGONIST MECHANISMS

Mechanism 1 - Reduced Aqueous Production:

Brimonidine → α₂ receptor on NPE (Gi-coupled)
    ↓ Gαi INHIBITS adenylyl cyclase
    ↓ ↓ cAMP → ↓ PKA
    ↓ ↓ Na⁺/K⁺-ATPase → ↓ ion/water secretion
    → ↓ Aqueous production (~20-25%)

Mechanism 2 - Increased Uveoscleral Outflow:

α₂ receptor stimulation in ciliary body
    ↓ Activates Gi → but also activates other pathways
    ↓ Reduces ciliary muscle tone
    ↓ Opens supraciliary space
    → ↑ Uveoscleral outflow

Mechanism 3 - Neuroprotection (Independent of IOP):

Brimonidine crosses blood-retinal barrier
    ↓ α₂ receptor on retinal ganglion cells (RGCs)
    ↓ Gi → inhibits adenylyl cyclase
    ↓ Also activates PI3K/Akt (survival pathway)
    ↓ ↑ Bcl-2 (anti-apoptotic protein)
    ↓ ↓ Caspase-3 activation
    → ↓ RGC apoptosis
    → Neuroprotective effect independent of IOP lowering

---

V. PROSTAGLANDIN ANALOG MECHANISMS

FP Receptor Signaling Cascade:

Latanoprost (prodrug)
    ↓ Corneal esterases (in epithelium)
    → Latanoprost FREE ACID (active metabolite)
    ↓ Binds FP receptor (Gαq/11 + Gα12/13 coupled)

Gαq/11 → PLC-β → IP3 + DAG
    IP3 → ↑ [Ca²⁺]ᵢ (from ER)
    DAG → PKC activation
    → Ciliary muscle cells: contraction/relaxation changes
    → TM cells: altered contractility

Gα12/13 → activates RhoGEF (guanine nucleotide exchange factor)
    → RhoA-GTP (active RhoA)
    → Activates ROCK (Rho-associated coiled-coil forming kinase)
    → ROCK phosphorylates MLC (myosin light chain) and inhibits MLC phosphatase
    (Note: in ciliary muscle, this leads to REMODELING rather than simple contraction)

Primary Mechanism: Uveoscleral Outflow Enhancement

FP receptor activation in ciliary muscle cells
    ↓
↑ Matrix metalloproteinase (MMP) expression:
    MMP-1 (interstitial collagenase)
    MMP-2 (gelatinase A)
    MMP-3 (stromelysin)
    MMP-9 (gelatinase B)
    ↓
Degradation of ECM components in ciliary muscle interstitial spaces:
    Collagen types I, III, IV
    Fibronectin
    Laminin
    ↓
↓ Resistance to aqueous flow through ciliary muscle
↑ Aqueous percolation through supraciliary/suprachoroidal spaces
→ ↑ UVEOSCLERAL OUTFLOW (~40-100% increase)
→ ↓ IOP 25-35%

• Slight increase in trabecular outflow (less well characterized)
• Ciliary muscle contractile changes that widen the uveoscleral drainage angle

Why Once-Daily Evening Dosing?

• Peak uveoscleral outflow enhancement occurs 8-12 hours after dosing
• IOP peaks in early morning (06:00-09:00) due to cortisol surge and positional changes
• Evening dosing at ~21:00-22:00 → peak effect at ~06:00-09:00, precisely when IOP is highest
• The ECM remodeling effect also means some IOP reduction is maintained even when drug levels fall

Iris Pigmentation Mechanism:

FP receptors on iris melanocytes
    ↓ FP activation
    → ↑ Melanogenesis via Gαq → PKC pathway
    → ↑ Tyrosinase activity (rate-limiting enzyme in melanin synthesis)
    → ↑ Eumelanin production in iris melanocytes
    → Irreversible iris darkening (blue/green → brown)

Latanoprostene Bunod (LBN) - Novel Mechanism:

LBN in eye
    ↓ Hydrolysis
    ↓
FP receptor activation     +    NO released
(uveoscleral pathway)           ↓
                           Activates soluble guanylyl cyclase (sGC)
                           ↓ ↑ cGMP
                           ↓ Activates PKG (cGMP-dependent protein kinase)
                           ↓ Dephosphorylates myosin
                           ↓ TM cell relaxation
                           ↓ ↑ TRABECULAR outflow

---

VI. CARBONIC ANHYDRASE INHIBITOR MECHANISMS

Aqueous Production - Biochemical Basis:

CO₂ + H₂O  ←—CA-II/CA-XII—→  H₂CO₃  →  H⁺ + HCO₃⁻

HCO₃⁻ transported via NBC1 (Na⁺/HCO₃⁻ cotransporter) and AE2 (Cl⁻/HCO₃⁻ exchanger)
    → HCO₃⁻ accumulates on basolateral side of NPE
    → Na⁺ follows HCO₃⁻ via Na⁺/K⁺-ATPase
    → Osmotic water flux → aqueous humor formed

CAI inhibits CA-II (and CA-XII) in NPE
    ↓
↓ HCO₃⁻ production
    ↓
↓ Anion accumulation in NPE
    ↓
↓ Na⁺ transport (follows HCO₃⁻)
    ↓
↓ Osmotic water flux
    ↓
↓ Aqueous humor secretion (~30-50%)
    ↓
↓ IOP

• Dorzolamide/brinzolamide topically have low systemic absorption
• They distribute to red blood cells (high CA-II in RBCs) → long t½ in blood (~147 days for dorzolamide in RBCs)
• But low plasma concentrations mean low renal CA inhibition → fewer systemic side effects than oral acetazolamide

---

VII. RHO KINASE (ROCK) INHIBITOR MECHANISMS

Background - Rho/ROCK Pathway in Trabecular Meshwork:

Normal TM:
Rho GTPase (RhoA) is tonically active
    → ROCK phosphorylates:
       (1) Myosin light chain (MLC) → actin-myosin contraction
       (2) MYPT1 (MLC phosphatase target subunit) → INHIBITS MLC phosphatase
    → Net: TM cells are contracted/stiff
    → HIGH RESISTANCE to aqueous outflow
    → Contributes to elevated IOP

Netarsudil (prodrug) → corneal esterase → AR-13503 (active metabolite)
    ↓
Inhibits ROCK1 and ROCK2 (competitive ATP-site inhibitor)
    ↓
↓ Phosphorylation of MLC (less myosin activation)
↓ MYPT1 phosphorylation → MLC phosphatase ACTIVATED → dephosphorylates MLC
    ↓
↓ Actin stress fiber formation in TM cells
↓ Focal adhesion formation
↓ Cell stiffness (TM cells become more compliant)
    ↓
↑ Paracellular spaces in TM and Schlemm's canal inner wall
↑ Conventional (TRABECULAR) outflow facility
    ↓
↓ IOP ~20-25%

Mechanism 2 - NET (Norepinephrine Transporter) Inhibition:

AR-13503 also inhibits NET (norepinephrine reuptake transporter) at sympathetic nerve terminals
    ↓
↑ Norepinephrine remains in synaptic cleft
↑ α₂ receptor stimulation (via NE)
    ↓
Gi → ↓ cAMP in ciliary body epithelium
    ↓
↓ Aqueous humor production

Mechanism 3 - Decreased Episcleral Venous Pressure (EVP):

ROCK inhibition in episcleral veins
    ↓
Vasodilation of episcleral venous plexus
    ↓
↓ EVP (from ~8-10 mmHg normally)
    ↓
IOP = F/C + EVP → if EVP ↓, IOP ↓ directly

---

VIII. OSMOTIC AGENT MECHANISMS

IV Mannitol → distributed in plasma (does NOT cross into eye - large molecule)
    ↓
Creates osmotic gradient: [Plasma] > [Vitreous humor]
    ↓
Water moves from vitreous/aqueous → plasma (osmosis down the gradient)
    ↓
↓ Vitreous volume → ↓ IOP dramatically (within 30-60 min)
    ↓
Also: vitreous dehydration creates "negative pressure" → reduces lens forward pressure

• Acute angle closure glaucoma (shrinks vitreous → lens moves back → angle opens)
• Pre-surgical vitreous dehydration (creates space for anterior segment surgery)

---

IX. LOCAL ANESTHETIC MECHANISMS

Proparacaine/Tetracaine (tertiary amine; pKa ~9)
    ↓ At physiologic pH, both neutral + ionized forms exist
    ↓ NEUTRAL form crosses lipid membrane of nerve cell
    ↓ Once inside cell, equilibrium → ionized (NH⁺) form predominates
    ↓ Ionized form enters Nav channel pore from INSIDE (use-dependent block)
    ↓ Binds to local anesthetic receptor in channel pore
       (segment S6 of domain IV in Nav1.7, Nav1.4)
    ↓ Physically occludes channel pore
    ↓ Channel cannot open → membrane cannot depolarize
    ↓ Action potential propagation BLOCKED in corneal sensory C and Aδ fibers
    → Anesthesia (loss of pain, touch, temperature)

• Loss of trophic support to corneal epithelium (neuropeptide substance P and CGRP from corneal nerves support epithelial cell renewal)
• Direct epithelial toxicity (detergent-like effect of high local concentrations)
• Impaired healing → neurotrophic keratopathy → corneal ulcer

---

X. ANTIBIOTIC MECHANISMS

1. Fluoroquinolones - DNA Gyrase & Topoisomerase IV Inhibition

Moxifloxacin/Ciprofloxacin enters bacterial cell
    ↓
GRAM-NEGATIVE primary target: DNA GYRASE (Topoisomerase II)
    - Subunits: GyrA (2) + GyrB (2) = A₂B₂ tetramer
    - Normal function: introduces negative supercoils ahead of replication fork
      (relieves torsional stress during DNA replication/transcription)
    ↓
GRAM-POSITIVE primary target: TOPOISOMERASE IV (ParC + ParE subunits)
    - Normal function: decatenation of daughter chromosomes after replication
    ↓
Drug-enzyme-DNA TERNARY COMPLEX forms:
    Fluoroquinolone intercalates between the cut strands
    + Binds enzyme at the break point
    ↓
Creates "roadblock": replication forks collide with frozen enzyme-DNA complexes
    ↓
Double-strand DNA BREAKS accumulate
    ↓ (two bactericidal mechanisms)
(1) SOS response: recA-mediated → DNA degradation + irregular cell division
(2) Direct cell death from dsDNA breaks even without SOS
    → BACTERICIDAL

• Inhibit BOTH DNA gyrase AND topoisomerase IV with high affinity
• For resistance by mutation to emerge, BOTH enzyme targets must mutate simultaneously
• Mutation frequency: ~10⁻¹⁶ vs ~10⁻⁸ for 2nd-generation FQs → much lower resistance potential

2. Aminoglycosides - Ribosomal Misreading

Tobramycin (polycationic, basic drug)
    ↓
Electrostatic attraction to negative charge of LPS (lipopolysaccharide) on outer membrane
    ↓
Displaces Mg²⁺/Ca²⁺ (cross-bridges holding LPS together) → outer membrane disruption
    ↓ Initial uptake (oxygen-dependent, killed by anaerobes)
    ↓
Enters cytoplasm → binds 16S rRNA on 30S ribosomal subunit
   (specifically the A-site on helix 44 of 16S rRNA)
    ↓
MISREADING mechanism:
    Normal: cognate tRNA with matched anticodon → exact amino acid insertion
    With aminoglycoside: drug distorts 16S rRNA A-site conformation
    → Near-cognate tRNAs (wrong amino acid) are accepted
    → MISINCORPORATION of amino acids → aberrant proteins
    ↓
Aberrant membrane proteins insert into cell membrane → INCREASED permeability
    ↓
More aminoglycoside enters → positive feedback → rapidly BACTERICIDAL
(Called the "self-promoted uptake" mechanism)

3. Chloramphenicol - Peptidyl Transferase Inhibition

Chloramphenicol → binds 23S rRNA on 50S ribosomal subunit
    ↓
Binds at the A-site of the PEPTIDYL TRANSFERASE CENTER (PTC)
    ↓
Blocks: aminoacyl-tRNA from entering the A-site
    ↓
Peptide chain CANNOT be elongated
    → BACTERIOSTATIC (does NOT kill; inhibits growth)

---

XI. ANTIVIRAL MECHANISMS

Acyclovir - Viral Selectivity Explained Step by Step

STEP 1 - ACTIVATION (key to selectivity):
Acyclovir (acycloguanosine) is a PRODRUG
    ↓
HSV-infected cells express viral THYMIDINE KINASE (TK)
    ↓
Viral TK phosphorylates acyclovir → acyclovir MONOPHOSPHATE (ACV-MP)
    (Human TK does this ~1000x LESS efficiently → minimal toxicity to normal cells)
    ↓
Cellular kinases: ACV-MP → ACV-DP → ACV-TP (acyclovir triphosphate)
    ↓

STEP 2 - CHAIN TERMINATION:
ACV-TP competes with dGTP (deoxy-guanosine triphosphate) for viral DNA polymerase
    ↓
ACV-TP has ~100-fold higher affinity for viral DNA pol than human DNA pol
    ↓
ACV-TP incorporated into growing viral DNA chain (in place of dGMP)
    ↓
PROBLEM: acyclovir lacks the 3'-OH group of normal nucleosides
    (acyclic side chain = no ring, no 3'-OH)
    ↓
DNA chain TERMINATES (no 3'-OH means next nucleotide cannot be added)
    ↓
ADDITIONALLY: viral DNA polymerase becomes irreversibly TRAPPED on the chain
    (suicidal enzyme inactivation)
    → Viral DNA replication completely halted
    → VIROSTATIC (prevents viral replication; does NOT kill existing virus)

• TK mutation: virus loses TK → cannot phosphorylate acyclovir → resistant (TK-deficient mutants)
• DNA pol mutation: altered polymerase has lower affinity for ACV-TP
• TK-negative mutants are less virulent (TK needed for efficient neuronal reactivation) but dangerous in immunocompromised patients
• Treatment of resistant HSV: Foscarnet (does NOT need TK activation - directly inhibits DNA pol) or cidofovir

Ganciclovir - Same but for CMV

Ganciclovir (GCV) in CMV-infected cells
    ↓
CMV UL97 kinase (NOT TK - different kinase) phosphorylates GCV → GCV-MP
    ↓
Cellular kinases → GCV-TP
    ↓
Inhibits CMV DNA polymerase (UL54)
    → Chain termination (like acyclovir)
    → CMV DNA replication inhibited

Foscarnet (phosphonoformate)
    ↓
DIRECTLY inhibits viral DNA polymerase at the PYROPHOSPHATE BINDING SITE
(blocks pyrophosphate release during nucleotide incorporation)
    ↓
Inhibits: HSV DNA pol, CMV DNA pol (UL54), HIV reverse transcriptase
    ↓
Does NOT need phosphorylation → effective even against TK-deficient (acyclovir-resistant) HSV

---

XII. ANTIFUNGAL MECHANISMS

Natamycin (Polyene) - Ergosterol Binding

Natamycin molecule contains a large lactone ring with alternating conjugated double bonds
    ↓
Binds ERGOSTEROL (primary sterol in fungal cell membranes)
    (Humans use CHOLESTEROL; this difference provides selectivity)
    ↓
Drug-ergosterol complex inserts into the membrane
    ↓
Forms PORES/CHANNELS (not a specific pore structure - general membrane disruption)
    ↓
K⁺ leaks out, small cations and molecules leak in
    ↓
Membrane potential collapses → cell contents leak out → FUNGICIDAL

Azoles (Voriconazole) - Ergosterol Synthesis Inhibition

Voriconazole enters fungal cell
    ↓
Inhibits CYP51 (lanosterol 14α-demethylase) - a fungal cytochrome P450 enzyme
    ↓
BLOCKS conversion: Lanosterol → Eburicol → (several steps) → Ergosterol
    ↓
Ergosterol NOT produced
    ↓
(1) Membrane loses fluidity (ergosterol maintains membrane function)
(2) Toxic methylated sterols (14α-methyl sterols) ACCUMULATE
    → Inhibit membrane-bound enzymes
    → Cell growth inhibited (FUNGISTATIC) or death (FUNGICIDAL for some)

---

XIII. CORTICOSTEROID MECHANISMS

At the Molecular Level:

Prednisolone acetate (lipophilic) penetrates cell membrane
    ↓
Binds cytoplasmic GLUCOCORTICOID RECEPTOR α (GRα) - a ligand-activated transcription factor
    ↓
Drug-GR complex dissociates from HSP90 (heat shock protein 90) chaperone
    ↓
GR undergoes conformational change → nuclear localization signals exposed
    ↓
Drug-GR complex translocates to NUCLEUS
    ↓
Dimerizes and binds GLUCOCORTICOID RESPONSE ELEMENTS (GREs) in DNA

1. TRANSACTIVATION (GRE-binding):
GR-GRE binding → ↑ transcription of:
    - Lipocortin 1 (Annexin A1): inhibits phospholipase A2 → ↓ arachidonic acid release
    - MAPK phosphatase-1 (MKP-1): inactivates ERK/JNK/p38 MAPK cascades
    - IκBα: inhibits NF-κB nuclear entry
    - IL-10: anti-inflammatory cytokine

2. TRANSREPRESSION (protein-protein interaction without DNA binding):
GR monomer directly interacts with:
    - NF-κB: blocks transcription of TNF-α, IL-1, IL-6, IL-8, COX-2, iNOS
    - AP-1 (Fos/Jun dimer): blocks matrix metalloproteinase production

3. NON-GENOMIC (rapid, within minutes):
    - Direct membrane effects on eicosanoid synthesis
    - Annexin-1 release → rapid PLA2 inhibition
    - Vasoconstrictive effect on conjunctival/corneal blood vessels (reduces redness)

• ↓ Prostaglandins (PLA2 inhibition) → ↓ vascular permeability, ↓ chemotaxis
• ↓ Cytokines (TNF-α, IL-1, IL-6) → ↓ cellular infiltration
• ↓ Histamine release from mast cells
• Stabilizes lysosomal membranes → ↓ tissue-damaging enzyme release

Steroid Glaucoma Mechanism:

Glucocorticoids in TM cells
    ↓ GR activation
    ↓ ↑ Myocilin (MYOC) expression
    ↓ Myocilin accumulates in TM ECM → glycosaminoglycan accumulation
    ↓ TM cells become stiffer (increased actin stress fibers, crosslinked ECM)
    ↓ ↓ Phagocytic activity of TM cells
    ↓ ↓ Conventional outflow facility
    ↓ ↑ IOP
    → STEROID-INDUCED OCULAR HYPERTENSION (SIOH) in ~30% of general population
       ("Steroid responders" have GRα polymorphisms with higher TM sensitivity)

Loteprednol - "Retro-metabolic" Design:

Loteprednol binds GR → anti-inflammatory effect (same genomic mechanism)
    ↓
After receptor binding, loteprednol undergoes PREDICTABLE OXIDATIVE METABOLISM
    → Converts to inactive metabolite Δ1-cortienic acid etabonate
    ↓
Inactive metabolite has NO glucocorticoid activity
→ ↓ Duration of action → ↓ cumulative steroid load in TM/lens
→ ↓ IOP elevation risk
→ ↓ PSC cataract risk

---

XIV. NSAID MECHANISMS

COX Inhibition Cascade:

Injury/inflammation → phospholipid membrane disruption
    ↓ Phospholipase A2 (PLA2)
    → ARACHIDONIC ACID released
    ↓ Cyclooxygenase-1 (COX-1) or COX-2
    → PGG2 (prostaglandin G2)
    ↓ Peroxidase activity of COX
    → PGH2 (prostaglandin H2)
    ↓
Tissue-specific synthases:
    PGH2 → PGE2 (by PGES) → pain, vasodilation, fever, hyperalgesia
    PGH2 → PGI2 (by PGIS) → vasodilation, inhibit platelet aggregation
    PGH2 → TXA2 (by TXAS) → vasoconstriction, platelet aggregation

Ketorolac/Diclofenac/Bromfenac
    ↓
Compete with arachidonic acid for the COX active site
    (fits into the hydrophobic channel of COX)
    ↓
↓ Prostanoid synthesis
    ↓
In eye: ↓ PGE2 → ↓ vascular permeability → ↓ CME
        ↓ PGI2 → ↓ vasodilation
        ↓ TXA2 → less effect on platelet aggregation (topical)
        ↓ Intraoperative PG release from iris trauma → prevents surgically-induced miosis
           (PGE2 normally released during surgical manipulation causes miosis via EP2/EP4 receptors)

Nepafenac → corneal amidases → AMFENAC (active NSAID)
    ↓
Amfenac penetrates corneal stroma and anterior chamber efficiently
    → Reaches the ciliary body and retina at higher concentrations
    → Better intraocular bioavailability vs diclofenac/ketorolac

---

XV. ANTI-VEGF BIOLOGIC MECHANISMS

VEGF Signaling Pathway (What these drugs block):

VEGF-A (165 isoform most important)
    ↓
Binds VEGFR-2 (KDR/Flk-1) → receptor DIMERIZES
    ↓
Dimerization → transphosphorylation of intracellular tyrosine kinase domains
    ↓
Phosphotyrosines recruit adaptor proteins:
    - PLCγ → IP3/DAG → Ca²⁺/PKC → proliferation, migration
    - PI3K → Akt/PKB → cell SURVIVAL, migration, VEGFR endocytosis
    - Ras/MAPK → ERK1/2 → proliferation, VEGF production (positive feedback)
    - eNOS phosphorylation → ↑ NO → vasodilation, ↑ vascular permeability
    - Src kinase → disrupts VE-cadherin at endothelial junctions → ↑ permeability
    ↓
NET EFFECTS in retinal pathology:
    ↑ Vascular permeability (endothelial junction disruption)
    ↑ Neovascularization (endothelial cell proliferation/migration)
    ↑ Macular edema (fluid accumulation in retinal layers)

Drug-Target Interactions:

• Binds all VEGF-A isoforms at the receptor-binding domain
• The Fab fragment (no Fc region) → CANNOT be recycled by FcRn → shorter vitreous half-life
• Does NOT bind VEGF-B, PlGF

• Same anti-VEGF-A epitope as ranibizumab (derived from same parent mouse antibody)
• Intact Fc → FcRn-mediated recycling → longer systemic half-life (concern for systemic anti-VEGF effects with intravitreal use via transscleral absorption)

Structure: VEGFR-1 D2 + VEGFR-2 D3 + IgG1 Fc

VEGFR-1 domain 2 binds: VEGF-A (all isoforms) + PlGF-1 + PlGF-2
VEGFR-2 domain 3 binds: VEGF-A (with very high affinity) + VEGF-B
IgG1 Fc: FcRn recycling (extends half-life in vitreous)

• Binding affinity for VEGF-A: Kd ~1 fM (vs ~60 fM for ranibizumab)
• ~100-fold higher affinity for VEGF-A than native receptors → acts as a "VEGF sink"
• PlGF blockade: important because PlGF is elevated in AMD and promotes macrophage-driven CNV
• High-dose 8 mg (Eylea HD): higher molar dose → longer duration of effect (q12-16 week dosing possible)

Faricimab - Bispecific Dual Pathway Block:

VEGF-A arm (ranibizumab-derived):
    Blocks VEGF-A → VEGFR-2 signaling (as above)
    → ↓ Neovascularization, ↓ vascular permeability

ANGIOPOIETIN-2 (Ang-2) arm:
    Background: Ang-1 binds Tie-2 receptor → STABILIZES vasculature
                (phosphorylates Tie2 → PI3K/Akt → promotes pericyte attachment,
                 tight junctions, endothelial survival)
    In disease: Ang-2 is UPREGULATED (released from Weibel-Palade bodies under stress)
                Ang-2 COMPETES with Ang-1 for Tie2 → BLOCKS Tie2 signaling
                → Pericyte dropout, tight junction disruption, inflammation, fibrosis

Faricimab → NEUTRALIZES Ang-2
    ↓
Ang-1/Tie2 signaling RESTORED (unopposed)
    ↓
PI3K → Akt activation in endothelial cells:
    ↑ VE-cadherin at junctions → tighter junctions → ↓ permeability
    ↑ Pericyte recruitment → vascular stability
    ↑ eNOS → anti-inflammatory signaling
    ↓ NF-κB → ↓ ICAM-1, ↓ VCAM-1 → ↓ leukostasis/inflammation
    ↓ Ang-2 activates integrin-αvβ3/αvβ5 → promotes ERM/fibrosis - BLOCKED

SYNERGY:
    VEGF-A blockade ↓ neovascularization (angiogenic drive)
    Ang-2 blockade ↓ vascular instability (stability pathway restored)
    Together: ↓ fluid, ↓ neovascularization, ↓ inflammation, ↓ fibrosis
    → More complete and durable vascular stabilization than anti-VEGF monotherapy

---

XVI. IMMUNOSUPPRESSANT MECHANISMS (DRY EYE)

Cyclosporine A - Calcineurin Inhibition:

Cyclosporine enters T-lymphocyte (especially CD4+ Th1 cells)
    ↓
Binds CYCLOPHILIN (cytoplasmic peptidyl-prolyl isomerase)
    ↓
CyA-Cyclophilin complex binds CALCINEURIN (Ca²⁺/CaM-dependent phosphatase)
    ↓
Calcineurin INHIBITED → cannot dephosphorylate NFAT (nuclear factor of activated T cells)
    ↓
NFAT-P (phosphorylated) cannot translocate to nucleus
    ↓
No NFAT binding to IL-2 gene promoter
    ↓
↓ IL-2 transcription → ↓ IL-2 production
    ↓
Without IL-2 autocrine signal, T cells CANNOT proliferate
    ↓
Downstream: ↓ IFN-γ, ↓ TNF-α, ↓ IL-1β production
    ↓
↓ Lacrimal gland inflammation
↓ Conjunctival T-cell density
↑ Goblet cell density (inflammatory suppression allows recovery)
↑ Tear production (lacrimal gland function restored)

Lifitegrast - LFA-1/ICAM-1 Blockade:

Dry eye inflammatory cycle:
Environmental stress → ↑ ICAM-1 on ocular surface epithelium
    ↓
ICAM-1 binds LFA-1 (lymphocyte function-associated antigen-1, an integrin α_L β_2)
    on T-lymphocyte surface
    ↓
LFA-1/ICAM-1 interaction activates T cell:
    (1) Provides co-stimulatory signal
    (2) Facilitates T cell migration and adhesion to ocular surface
    ↓
T cells activated → ↑ IL-1β, ↑ MMP-3, ↑ MMP-9 → damage mucins, goblet cells
    ↓ Tear stability → ↑ osmolarity → ↑ stress → MORE ICAM-1 (vicious cycle)

Lifitegrast blocks:
LFA-1 (binds to α_L subunit I-domain - same site as ICAM-1 but non-competitive
 - it occupies the binding groove, preventing ICAM-1 from inserting)
    ↓
No LFA-1/ICAM-1 ligation → T cell NOT co-stimulated
    ↓
↓ T cell activation, ↓ T cell migration to ocular surface
    ↓
↓ IL-1β, ↓ TNF-α, ↓ MMPs → ↓ inflammation → ↓ dry eye symptoms

---

XVII. BOTULINUM TOXIN MECHANISM

Botulinum toxin type A (BoNT-A) is a ~150 kDa zinc metalloprotease
    ↓
STEP 1 - BINDING:
Heavy chain (HC, C-terminal) binds polysialoganglioside receptors (GT1b, GD1a)
+ SV2C (synaptic vesicle protein 2C) at presynaptic cholinergic nerve terminals
    ↓
STEP 2 - ENDOCYTOSIS:
Receptor-mediated endocytosis → BoNT-A enters acidic endosome
    ↓
STEP 3 - TRANSLOCATION:
Acid-induced conformational change → light chain (LC) translocates across
endosomal membrane into cytosol (pore-forming mechanism of HC N-terminal domain)
    ↓
STEP 4 - PROTEOLYSIS:
LC is a zinc-dependent endopeptidase
BoNT-A specifically cleaves SNAP-25 (synaptosomal-associated protein 25 kDa)
    at a single Gln197-Arg198 peptide bond
    ↓
SNAP-25 is a component of the SNARE complex:
    (SNARE = Soluble NSF Attachment protein Receptor)
    VAMP/synaptobrevin (on vesicle) + SNAP-25 (on plasma membrane) + Syntaxin-1 (on PM)
    form the SNARE complex → drives membrane fusion → ACh vesicle exocytosis
    ↓
With SNAP-25 cleaved → SNARE complex CANNOT form → NO vesicle fusion
    ↓
No ACh released at neuromuscular junction → muscle CANNOT contract
    ↓ (at extraocular muscles)
Muscle weakened/paralyzed
    ↓
REVERSIBILITY: New SNAP-25 synthesized over 3-4 months → function returns gradually

• Strabismus: Injected into overacting rectus muscle → temporary paralysis → allows antagonist to tighten → long-term alignment correction (even after toxin wears off)
• Blepharospasm: Injected into orbicularis oculi → ↓ spasm → improved eye opening
• Lid retraction in thyroid eye disease: ↓ superior tarsal muscle (Müller's) and levator action

---

XVIII. ANTIALLERGIC MECHANISM - MAST CELL PATHWAY

Complete allergic conjunctivitis cascade:

SENSITIZATION:
Allergen → corneal/conjunctival antigen-presenting cells (APCs)
    ↓ Process and present to CD4+ T cells (Th2 polarization)
    ↓ IL-4, IL-13 production by Th2 cells
    ↓ B cell class switch → IgE production
    ↓ IgE binds FcεRI (high-affinity IgE receptor) on MAST CELLS
    (conjunctival mast cells: ~50 million/eye; palpebral > bulbar)

RE-EXPOSURE (EARLY PHASE, seconds-minutes):
Allergen cross-links IgE-FcεRI complexes on mast cell surface
    ↓
FcεRI receptor aggregation → activation of:
    (1) Lyn kinase (Src family) → phosphorylates ITAMs on FcεRI
    (2) Syk kinase → recruited and activated
    (3) LAT scaffold phosphorylated → recruits PLCγ
    ↓
PLCγ → IP3 + DAG
IP3 → ER Ca²⁺ release + CRAC channel opening (SOCE) → ↑ [Ca²⁺]ᵢ
DAG → PKC activation
    ↓
Ca²⁺-dependent DEGRANULATION:
    Preformed mediators RELEASED:
    - HISTAMINE → H1 receptors on conjunctival vessels + sensory nerves
      → vasodilation, ↑ permeability (edema/chemosis), pruritus
    - Tryptase (marker of mast cell degranulation)
    - Heparin, proteoglycans

LATE PHASE (2-4 hours):
Newly synthesized mediators (from arachidonic acid):
    - PGD2 → DP2 receptor → Th2 chemotaxis
    - LTC4/D4/E4 (cysteinyl leukotrienes) → further permeability, chemotaxis
    - PAF → eosinophil recruitment
    ↓
Eosinophil infiltration → eosinophil cationic protein (ECP), MBP → corneal damage (VKC)

• Cromolyn/Lodoxamide (mast cell stabilizers): Inhibit Cl⁻ channel opening that normally follows Ca²⁺ influx during mast cell activation → prevents degranulation. Must be used BEFORE allergen exposure (prophylactic only).
• H1 antihistamines (olopatadine, ketotifen): Competitive antagonists at H1 receptor on:
  • Conjunctival vessels → block histamine-mediated vasodilation/permeability
  • Sensory nerve endings → block histamine-mediated itch (pruritus via TRPV1/TRPA1 potentiation by H1 signaling on C fibers)
• Dual agents (olopatadine): BOTH block H1 AND prevent mast cell degranulation (blocks calcium influx) → cover both the symptom AND the release.
• Alcaftadine (unique): Also blocks H2 receptors (which mediate pruritus via different pathway) + prevents eosinophil transmigration → useful in severe VKC.

---

MECHANISM SUMMARY TABLE

---

• Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Ed, Chapter 74 (direct reading)
• Miller's Anesthesia, 10th Ed (aqueous humor physiology, IOP anatomy)
• ROCK inhibitors mechanism review: PMID 37837578
• Faricimab Ang-2/VEGF dual mechanism: PMID 39708087
• Glucocorticoid-induced IOP mechanism: PMID 38379915

---

What You Have - Strengths

---

What Might Still Be Asked - Gaps to Address

1. Specific Dosing / Preparation Details

• "What is the concentration of pilocarpine used in glaucoma?" (1-4%)
• "What is the dose of intravitreal bevacizumab?" (1.25 mg/0.05 mL)
• "What are the contents of Tobradex?" (tobramycin 0.3% + dexamethasone 0.1%)

2. Drug Interactions Table

• Brimonidine + MAO inhibitors (dangerous hypertensive/hypotensive crisis)
• Topical beta-blockers + systemic beta-blockers (additive cardiovascular depression)
• Fluoroquinolones + antacids/metal cations (chelation - less relevant for ophthalmic drops but asked in theory)
• Cyclosporine + CYP3A4 inhibitors (azoles raise systemic cyclosporine levels)

3. Specific Conditions → Drug of Choice

4. Fluorescein Staining Patterns

• Rose Bengal: stains dead/devitalized epithelial cells (not covered in detail)
• Lissamine green: similar to rose Bengal, better tolerated
• Fluorescein: stains denuded epithelium (covered)
• These are short 2-mark questions but easy marks

5. Short Notes Commonly Asked in Theory

• Ocusert (pilocarpine sustained release insert)
• Durysta (intracameral bimatoprost implant)
• Miotics in glaucoma (with a diagram of TM mechanism)
• Steroid responders (mechanism of steroid glaucoma)
• Preservative toxicity of BAK (already covered well)
• Topical anesthetic abuse (neurotrophic keratopathy mechanism - covered)

6. What Was NOT Covered At All

• Subconjunctival/retrobulbar injection technique and drugs (lignocaine + hyaluronidase for peribulbar block)
• Hyaluronidase used in periocular blocks (breaks hyaluronic acid in tissues → improves spread of LA)
• Viscoelastics in more detail (cohesive vs dispersive classification for exam)
• Enzymatic vitreolysis - Ocriplasmin (jetrea): serine protease that cleaves fibronectin and laminin at vitreoretinal interface for vitreomacular traction

---

Honest Bottom Line

---

MD Ophthalmology - Honest Assessment & What You Still Need

Straight Answer First

---

What MD Ophthalmology Examiners Actually Ask (Based on Pattern Analysis)

Category 1: "Explain your choice of drug in this clinical scenario"

Category 2: Surgical pharmacology (a major gap in what was covered)

Category 3: Drug monitoring protocols with specific thresholds

Category 4: Emerging/pipeline drugs (expected at MD level)

Category 5: Pharmacology of specific diseases as a whole (not just drug classes)

---

SUPPLEMENTARY CONTENT FOR MD OPHTHALMOLOGY

---

A. VISCOELASTICS - OPHTHALMIC VISCOSURGICAL DEVICES (OVDs)

Classification by Rheological Properties

• Cohesive OVDs: High molecular weight, high viscosity, high elasticity. Molecules stay together (cohesive). Maintain space well. Easy to remove in one piece at end of surgery.
• Dispersive OVDs: Lower molecular weight, lower viscosity, low surface tension. Coat surfaces. Do NOT maintain space as well. Harder to completely remove (fragments remain).

Specific Agents

• Glycosaminoglycan; negatively charged; binds water (holds 1000x its weight in water)
• Healon (1% HA, MW ~4 million Da): Cohesive; excellent space maintenance
• Healon GV (1.4% HA, MW ~5 million Da): Even more cohesive; "super cohesive"
• Healon 5 (2.3% HA): Viscoadaptive - behaves cohesively at low flow (maintains space) and dispersively at high phaco power (protective coating) → "viscoadaptive" or "viscous dispersive" behavior
• Provisc (1% HA): Similar to Healon; from Alcon
• Viscoat (4% HA + 3% chondroitin sulfate): Dispersive; best endothelial protection during phaco

• Sulfated glycosaminoglycan; negatively charged; lubricative
• Used in combination with HA (Viscoat); CS alone is low molecular weight → dispersive behavior

• Semi-synthetic polymer; 2% HPMC
• Much cheaper than HA-based OVDs
• Intermediate viscosity; less cohesive than Healon
• Widely used in low-resource settings; adequate for routine cataract surgery
• Degrades slower than HA → slightly higher risk of post-op IOP spike

• Orcolon: rarely used now

"Soft Shell" Technique (Arshinoff):

1. Inject Viscoat (dispersive) first - fills posterior chamber and coats endothelium
2. Inject Healon (cohesive) on top - pushes Viscoat to periphery and back, maintains working space centrally
3. After phaco: Cohesive Healon removed easily first; Viscoat (which protected endothelium throughout) removed last

• This gives maximum endothelial protection (dispersive) PLUS maximum space maintenance (cohesive)

Post-Operative IOP Spike Mechanism:

• Cohesive OVDs: large molecules → TM physically blocked → larger IOP spike but shorter duration (cleared faster)
• Dispersive OVDs: smaller, stickier → TM coated with thin layer → smaller spike but more prolonged
• Prevention: thorough removal at end of surgery; brimonidine drops post-op

---

B. OCULAR ANESTHESIA FOR SURGERY - COMPLETE

Topical Anesthesia (for cataract surgery)

• Proparacaine 0.5% + intracameral lidocaine 1% (preservative-free, 0.5 mL)
• Safest; no risk of retrobulbar hemorrhage, globe perforation, brainstem anesthesia
• Requires cooperative patient; no akinesia

Peribulbar Block (preferred over retrobulbar now)

• Lignocaine (lidocaine) 2%: Onset 2-5 min, duration 1-2 hrs; amide LA
• Bupivacaine 0.5%: Onset 10-15 min, duration 4-6 hrs; amide LA; for longer procedures
• Mixture: Lignocaine 2% + Bupivacaine 0.5% (rapid onset of lignocaine + long duration of bupivacaine)
• Hyaluronidase 3-7.5 IU/mL: Added to LA mixture
  • Mechanism: Depolymerizes hyaluronic acid in the orbital connective tissue matrix (hydrolyzes β-1,4 glycosidic bonds) → breaks down "tissue cement" → improves spread of LA through orbital fat → better akinesia with smaller volume, less orbital pressure, less risk of globe perforation
  • Does NOT prolong anesthesia; purely enhances spread
• Epinephrine 1:100,000 (sometimes): Vasoconstriction → slows LA absorption → prolongs duration + reduces systemic toxicity

Retrobulbar Block (now less preferred)

• Drug: Lignocaine 2% ± bupivacaine, with hyaluronidase
• Injected behind the globe, within the muscle cone
• Better akinesia, less volume needed
• Higher risk: retrobulbar hemorrhage, globe perforation (esp myopic eyes), optic nerve damage, brainstem anesthesia (via spread along optic nerve sheath), oculocardiac reflex

Sub-Tenon's Anesthesia

• Drug: Lignocaine 2% (2-5 mL)
• Cannula inserted through small conjunctival incision into sub-Tenon's space
• No needle near orbit → safer; good for posterior segment surgery
• Provides analgesia + akinesia

EMLA Cream (periocular)

• Eutectic mixture of lignocaine 2.5% + prilocaine 2.5%
• Applied to eyelids; provides surface anesthesia for minor lid procedures

Oculocardiac Reflex (OCR) - Pharmacological Management

• Triggered by traction on extraocular muscles (especially medial rectus) or pressure on globe
• Afferent: Ophthalmic branch of trigeminal (V1) → Gasserian ganglion → trigeminal sensory nucleus
• Efferent: Vagus nerve → cardiac slowing (bradycardia, asystole)
• Prevention/treatment: IV atropine 0.01-0.02 mg/kg; retrobulbar block reduces incidence; stop surgical manipulation

---

C. DRUG MONITORING PROTOCOLS - CRITICAL FOR MD VIVA

Hydroxychloroquine (HCQ) Retinopathy Monitoring

• Daily dose >5 mg/kg/day (real body weight - Melles/Marmor 2016)
• Duration >5 years (cumulative dose >1000 g)
• Renal/hepatic impairment (reduced clearance)
• Pre-existing macular disease
• Concomitant tamoxifen use (synergistic toxicity - 5-fold increased risk)

• Baseline: Fundus exam, visual fields (10-2 Humphrey), SD-OCT (macular thickness), multifocal ERG (mfERG) if available
• Annual screening from year 5: 10-2 automated perimetry + SD-OCT (look for parafoveal thinning of outer nuclear layer/IS-OS disruption) ± mfERG
• High risk patients: Screen from year 1
• Earliest sign on SD-OCT: Parafoveal outer retinal layer thinning (photoreceptor loss before RPE loss)
• Drug does NOT have to be stopped for early subclinical changes; stop when definite toxicity appears
• Toxicity partially reversible in early stages; irreversible once advanced

Ethambutol Optic Neuropathy Monitoring

• Mechanism: Chelates zinc in retinal ganglion cells and optic nerve → inhibits mitochondrial function → axonal degeneration
• Risk: Dose-dependent; >15 mg/kg/day significantly higher risk
• Monitoring: Color vision (Ishihara/FM-100) + visual field (central scotoma) monthly; discontinue immediately if changes detected
• Recovery: Slow and incomplete after optic neuropathy established

Vigabatrin (Anticonvulsant) - Ophthalmic Monitoring

• Mechanism of damage: GABA transaminase inhibitor → GABA accumulation in inner retina → cone photoreceptor dysfunction (mechanism not fully established but related to GABA toxicity in müller cells)
• Effect: Bilateral concentric visual field constriction (permanent, irreversible)
• Monitoring: Perimetry every 3-6 months; ERG changes may precede field loss

---

D. SURGICAL PHARMACOLOGY - GAPS FILLED

Ocriplasmin (Jetrea) - Enzymatic Vitreolysis

• Ocriplasmin is a recombinant truncated form of human plasmin (serine protease, 27 kDa)
• Cleaves fibronectin (Arg-Gly bond) and laminin → these are adhesion proteins at the vitreoretinal interface
• Normal vitreoretinal adhesion: cortical vitreous collagen + hyaluronan + fibronectin + laminin + integrins bind to ILM (internal limiting membrane) of retina
• Ocriplasmin cleaves fibronectin and laminin → enzymatic separation of posterior vitreous face from ILM → pharmacological posterior vitreous detachment (PVD)
• Also partially degrades vitreous collagen structure

Tissue Plasminogen Activator (tPA) - Intraocular Use

• Mechanism: Serine protease; converts plasminogen → plasmin → fibrin degradation (fibrinolysis)
• Alteplase (recombinant tPA): 25-50 µg intravitreal for submacular hemorrhage (subretinal)
• Pneumatic displacement technique: Intravitreal tPA + SF6 gas → patient face-down → tPA liquefies submacular clot → gas pushes it inferiorly → improved vision
• Intracameral tPA: 3-12.5 µg for fibrinous anterior chamber exudate post-surgery, post-trabeculectomy fibrin

Bevacizumab for Retinopathy of Prematurity (ROP)

• BEAT-ROP trial: Bevacizumab 0.625 mg IV superior to laser for Zone I Stage 3+ ROP
• Mechanism advantage in ROP: Anti-VEGF reduces neovascularization without destroying peripheral retina (laser destroys it); allows peripheral retinal vascularization to complete
• Concern: Systemic anti-VEGF exposure in premature infants may affect developing organs (brain, kidney, lung) → serum VEGF suppressed for weeks
• Aflibercept 0.4 mg: FDA-approved 2023 specifically for ROP (first FDA approval for ROP pharmacotherapy)
• Ranibizumab 0.2 mg (Byooviz, Cimerli): Used off-label in some centers

Subconjunctival/Sub-Tenon's Injections - Drugs Used

Intracameral Drugs (Inside Anterior Chamber)

---

E. NEUROPROTECTION IN GLAUCOMA - MD-LEVEL TOPIC

1. Glutamate excitotoxicity: Elevated vitreous glutamate → overactivation of NMDA receptors on RGCs → excessive Ca²⁺ influx → mitochondrial dysfunction → apoptosis
2. Oxidative stress: Superoxide, hydrogen peroxide → lipid peroxidation → RGC death
3. Neurotrophic factor deprivation: BDNF/TrkB retrograde transport blocked at compressed lamina cribrosa → RGC soma loses survival signal
4. Neuroinflammation: Activated microglia, complement deposition at RGC synapses (synapse elimination)
5. Vascular dysregulation: Impaired ocular blood flow → ischemia-reperfusion

---

F. DRY EYE PHARMACOLOGY - COMPLETE MD-LEVEL COVERAGE

Treatment Ladder (DEWS II + Current Practice)

Step 1: Artificial tears + lid hygiene
Step 2: Cyclosporine / Lifitegrast + omega-3 supplements + short steroid pulse
Step 3: Serum tears + therapeutic contact lenses + punctal plugs (semi-permanent)
Step 4: Surgery (permanent punctal occlusion, tarsorrhaphy, salivary gland transplant)

Newest Agents (post-2021 FDA approvals):

• Mechanism: Semifluorinated alkane; completely different from all previous dry eye drugs
• Applied as a pure liquid (not aqueous); low surface tension (14 mN/m vs water ~72 mN/m)
• Spreads uniformly over tear film surface → forms stable lipid layer substitute on top of aqueous layer
• Reduces evaporative water loss from ocular surface (by ~30%) → addresses evaporative dry eye specifically
• Does NOT contain water, preservatives, buffers → no preserved formulation needed
• Targets the root cause of Meibomian Gland Dysfunction (MGD)-related dry eye
• Clinical trial: GOBI and MOJAVE Phase 3 trials → significant reduction in total corneal fluorescein staining and dryness score vs vehicle
• Meta-analysis 2025 confirms efficacy (PMID 39622217)

• Mechanism: Partial agonist at nicotinic acetylcholine receptors (nAChRs) on nasal mucosa → activates trigeminal-lacrimal reflex arc → stimulates lacrimal gland via parasympathetic efferents → increases basal tear secretion
• Completely different mechanism - works via neural stimulation, not anti-inflammatory, not barrier repair
• Addresses aqueous deficiency dry eye
• Intranasal route; systemic absorption minimal; no CNS effects at this dose

• Same calcineurin mechanism as Restasis 0.05% but higher concentration and better bioavailability via nanomicellar technology (smaller particle size → better corneal penetration)
• Faster onset and greater tear volume increase vs Restasis

---

G. COMPARATIVE PHARMACOLOGY TABLES (What Examiners Love)

Anti-VEGF Comparison - MD Level Detail

Prostaglandin Analog Comparison

---

H. DRUG INTERACTIONS - RAPID REFERENCE FOR VIVA

---

I. WHAT AN MD OPHTHALMOLOGY EXAMINER WILL ASK IN VIVA - PREDICTED QUESTIONS WITH ANSWERS

---

FINAL VERDICT: MD OPHTHALMOLOGY